ArticleClinics (Sao Paulo, Brazil)2026
Investigation of molecular immune regulation mechanisms and therapeutic target prediction in pancreatic cancer based on bioinformatics and genetics.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePancreatic Cancer (PC) is a highly aggressive malignancy with a dismal prognosis, primarily due to late-stage diagnosis and limited therapeutic options. This study aimed to identify potential biomarkers involved in PC progression and immune microenvironment modulation.
methodsRNA sequencing data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases were integrated to identify differentially expressed genes. Mendelian Randomization (MR) analysis was conducted to assess causal associations between candidate genes and PC risk. Immune cell infiltration was evaluated using the CIBERSORT algorithm, and mediation analysis explored the role of immune cells in PC progression. Validation was performed using RT-qPCR and immunohistochemistry in clinical tissue samples.
resultsCLIC3 and MST1R were significantly overexpressed in PC tissues and associated with advanced tumor stages. MR analysis confirmed their causal relationship with PC, with Odds Ratios of 2.36 (95% CI: 1.58-3.51) for CLIC3 and 1.30 (95% CI: 1.06-1.60) for MST1R. High expression of these genes correlated with increased M0 macrophages and decreased CD8⁺ T cells, CD4⁺ T-cells, and naïve B-cells, suggesting immune dysregulation. Mediation analysis emphasized the pivotal role of CD8⁺ cytotoxic T-cells in PC progression. Moreover, CLIC3 and MST1R were closely associated with immune checkpoint molecules CD276 and NT5E.
conclusionsCLIC3 and MST1R are overexpressed and causally implicated in pancreatic cancer development and immune modulation. They represent promising biomarkers and potential therapeutic targets for precision immunotherapy in PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.